• Skip to primary navigation
  • Skip to main content

Stanford Alliance for Primary Immunodeficiency

Stanford University

  • SAPI
  • Stanford PI Clinic
  • Patient Support
    • Diagnosis
    • Treatment and Complications
    • School
    • Work
    • Parenting
    • Sibling
    • Lifestyle
    • Mentorship Program
    • PI Resources
      • Immune Deficiency Foundation (IDF)
      • Jeffrey Modell Foundation
      • Painted Turtle Camp
      • Make-A-Wish
      • Baxter IVIG
      • CSL Behring IVIG
  • Kids’ Zone
    • Kids’ Zone
    • Pre-Teen FAQ
    • Teen FAQ
  • PID Research
    • Butte Lab Immunology Research Projects
    • PID Research blog
  • Local Events
  • Donate
You are here: Home / Archives for Research

Research

Stem cell transplantation for primary immunodeficiency diseases: the North American experience.

September 27, 2014 By Manish Butte

Related Articles

Stem cell transplantation for primary immunodeficiency diseases: the North American experience.

Curr Opin Allergy Clin Immunol. 2014 Sep 24;

Authors: Pai SY, Cowan MJ

Abstract
PURPOSE OF REVIEW: This review describes recent studies on outcomes after allogeneic hematopoietic cell transplantation for primary immunodeficiency in North America, including severe combined immunodeficiency (SCID), Wiskott-Aldrich syndrome and chronic granulomatous disease.
RECENT FINDINGS: Using uniform diagnostic criteria, the Primary Immune Deficiency Treatment Consortium described the baseline characteristics of newly diagnosed infants with SCID in North America. Analysis of outcomes of hematopoietic cell transplantation for SCID in North America from 2000 to 2009 showed that young infants, and older infants without active infection, had excellent survival irrespective of type of donor or transplant approach with regard to conditioning. Although pretransplant conditioning with chemotherapy had a clear and strong negative impact on survival in infants with active infection at the time of transplant, among survivors, conditioning was associated with improved immune reconstitution. However, the potential late effects of conditioning in these infants remain to be characterized. Advances in transplant outcomes for Wiskott-Aldrich syndrome and chronic granulomatous disease support the strategy of early transplantation before the onset of severe complications; additional multicenter studies are needed to fully define optimal approaches.
SUMMARY: The formation of the Primary Immune Deficiency Treatment Consortium, a multiinstitutional North American consortium, has contributed to our understanding of outcomes after transplant for primary immunodeficiency.

PMID: 25259542 [PubMed – as supplied by publisher]

Powered by WPeMatico

Filed Under: Research

A rare primary immunodeficiency.

September 26, 2014 By Manish Butte

A rare primary immunodeficiency.

BMJ Case Rep. 2014;2014

Authors: Nagaraj P, Sivathanu S, Sampath S, Ramakrishnan N

Abstract
A 9-year-old girl presented with failure to thrive, chronic mucopurulent nasal discharge, recurrent skin pustules and recurrent episodes of purulent ear discharge since 2 years of age. She had coarse facial features with extensive eczema, multiple pyoderma scars, florid dental caries, retained primary dentition, hypermobile joints and a woody induration of the vulva. Autosomal dominant hyper-IgE syndrome was suspected and confirmed by very high serum IgE levels. Vulval biopsy revealed a premalignant condition. STAT 3 mutation, which is usually responsible for this condition, was not found in our case, indicating an as yet unidentified mutation. The child also had unusual features like the total absence of clinical and radiological features of pneumonia. The premalignant change in the vulva was also unusual since vulval carcinoma has not been reported so far in children with this disorder. This child will require a close follow-up to look for malignant transformation.

PMID: 25253482 [PubMed – as supplied by publisher]

Powered by WPeMatico

Filed Under: Research

Calculated globulin (CG) as a screening test for antibody deficiency.

September 25, 2014 By Manish Butte

Related Articles

Calculated globulin (CG) as a screening test for antibody deficiency.

Clin Exp Immunol. 2014 Sep;177(3):671-8

Authors: Jolles S, Borrell R, Zouwail S, Heaps A, Sharp H, Moody M, Selwood C, Williams P, Phillips C, Hood K, Holding S, El Shanawany T

Abstract
Calculated globulin (total protein – albumin) is usually tested as part of a liver function test profile in both primary and secondary care and determines the serum globulin concentration, of which immunoglobulins are a major component. The main use hitherto of calculated globulin is to detect paraproteins when the level is high. This study investigated the potential to use low levels of calculated globulin to detect antibody deficiency. Serum samples with calculated globulin cut-off < 18 g/l based on results of a pilot study were collected from nine hospitals in Wales over a 12-month period. Anonymized request information was obtained and the samples tested for immunoglobulin levels, serum electrophoresis and, if appropriate, immunofixation. A method comparison for albumin measurement using bromocresol green and bromocresol purple was undertaken. Eighty-nine per cent (737 of 826) samples had an immunoglobulin (Ig)G level of < 6 g/l using the bromocresol green methodology with a cut-off of < 18 g/l, and 56% (459) had an IgG of < 4 g/l. Patients with both secondary and primary antibody deficiency were discovered and serum electrophoresis and immunofixation showed that 1·2% (10) had previously undetected small paraproteins associated with immune-paresis. Using bromocresol purple, 74% of samples had an IgG of < 6 g/l using a cut-off of < 23 g/l. Screening using calculated globulin with defined cut-off values detects both primary and secondary antibody deficiency and new paraproteins associated with immune-paresis. It is cheap, widely available and under-utilized. Antibody-deficient patients have been discovered using information from calculated globulin values, shortening diagnostic delay and time to treatment with immunoglobulin replacement therapy.

PMID: 24784320 [PubMed – indexed for MEDLINE]

Powered by WPeMatico

Filed Under: Research

Altered Serum Cytokine Signature in Common Variable Immunodeficiency.

September 24, 2014 By Manish Butte

Altered Serum Cytokine Signature in Common Variable Immunodeficiency.

J Clin Immunol. 2014 Sep 23;

Authors: Hel Z, Huijbregts RP, Xu J, Nechvatalova J, Vlkova M, Litzman J

Abstract
PURPOSE: Common variable immunodeficiency (CVID) is the most frequent form of primary symptomatic hypogammaglobulinemia. CVID patients display a number of abnormalities in lymphocyte subpopulations including chronic T-cell activation and decreased numbers of circulating CD4(+) T cells and NK cells. We and others have recently shown that CVID is associated with increased concentration of soluble CD14 (sCD14) and other factors indicating limited microbial translocation.
METHODS: To address the mechanisms of chronic immune activation in CVID, we performed a detailed analysis of cytokine serum levels in 36 patients with CVID, 52 patients with selective IgA deficiency (IgAD), and 56 healthy volunteers.
RESULTS: We show that CVID is associated with elevated serum levels of CXCL-10/IP-10, IL-1R antagonist, TNF-α, IL-10, IL-12 (p40), CCL-2/MCP-1, G-CSF, and CCL-11/eotaxin. The detected cytokine signature is consistent with an ongoing activation of cells of myeloid lineage. In contrast, the levels of cytokines typically produced by CD4(+) T helper cells of Th1 (IFN-γ, IL-2), Th2 (IL-9, IL-13), and Th17 (IL-17) subtypes were suppressed in CVID patients compared to healthy donors.
CONCLUSIONS: Presented data suggest that the altered cytokine profile observed in patients with CVID may be attributed to the activation of monocyte-macrophage and granulocyte lineages, possibly driven by the translocation of bacterial components across the gastrointestinal or respiratory tracts mucosal barrier.

PMID: 25246148 [PubMed – as supplied by publisher]

Powered by WPeMatico

Filed Under: Research

RAG1/2 knockout pigs with severe combined immunodeficiency.

September 23, 2014 By Manish Butte

Related Articles

RAG1/2 knockout pigs with severe combined immunodeficiency.

J Immunol. 2014 Aug 1;193(3):1496-503

Authors: Huang J, Guo X, Fan N, Song J, Zhao B, Ouyang Z, Liu Z, Zhao Y, Yan Q, Yi X, Schambach A, Frampton J, Esteban MA, Yang D, Yang H, Lai L

Abstract
Pigs share many physiological, biochemical, and anatomical similarities with humans and have emerged as valuable large animal models for biomedical research. Considering the advantages in immune system resemblance, suitable size, and longevity for clinical practical and monitoring purpose, SCID pigs bearing dysfunctional RAG could serve as important experimental tools for regenerative medicine, allograft and xenograft transplantation, and reconstitution experiments related to the immune system. In this study, we report the generation and phenotypic characterization of RAG1 and RAG2 knockout pigs using transcription activator-like effector nucleases. Porcine fetal fibroblasts were genetically engineered using transcription activator-like effector nucleases and then used to provide donor nuclei for somatic cell nuclear transfer. We obtained 27 live cloned piglets; among these piglets, 9 were targeted with biallelic mutations in RAG1, 3 were targeted with biallelic mutations in RAG2, and 10 were targeted with a monoallelic mutation in RAG2. Piglets with biallelic mutations in either RAG1 or RAG2 exhibited hypoplasia of immune organs, failed to perform V(D)J rearrangement, and lost mature B and T cells. These immunodeficient RAG1/2 knockout pigs are promising tools for biomedical and translational research.

PMID: 24973446 [PubMed – indexed for MEDLINE]

Powered by WPeMatico

Filed Under: Research

Healing of Granulomatous Skin Changes in Ataxia-Telangiectasia After Treatment with Intravenous Immunoglobulin and Topical Mometasone 0.1% Ointment.

September 23, 2014 By Manish Butte

Related Articles

Healing of Granulomatous Skin Changes in Ataxia-Telangiectasia After Treatment with Intravenous Immunoglobulin and Topical Mometasone 0.1% Ointment.

Pediatr Dermatol. 2014 Sep 18;

Authors: Privette ED, Ram G, Treat JR, Yan AC, Heimall JR

Abstract
Ataxia-telangiectasia (AT) is a rare autosomal recessive disorder characterized by faulty DNA damage repair. The disease affects multiple systems and is noted to be particularly difficult to diagnose in children because of the wide spectrum of clinical presentations. We present an unusual case of a child in whom the primary cutaneous manifestation of AT was noninfectious cutaneous caseating granulomas. A 3-year-old girl presented to the emergency department with ataxia, poor growth, and multiple ulcerated plaques on both upper extremities that had been present for 2 years. She had two prolonged hospitalizations and underwent extensive examination to identify an etiology for the skin lesions. She was diagnosed with AT after immunology examinaton and genetic testing. Outpatient intravenous immunoglobulin (IVIG) therapy was initiated and she was prescribed twice-daily mometasone 0.01% ointment under occlusion. After 6 weeks on this regimen her lesions had completely healed. Twenty-two cases of AT have been reported in which patients presented with cutaneous granulomas. This report demonstrates the first reported case in which the granulomatous skin lesions of AT healed after aggressive application of topical steroids with concurrent IVIG therapy, without oral steroids. A brief review of cutaneous granulomas in the setting of immunodeficiency is also presented.

PMID: 25236668 [PubMed – as supplied by publisher]

Powered by WPeMatico

Filed Under: Research

Cost-Minimization Analysis of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients With Primary Immunodeficiency.

September 23, 2014 By Manish Butte

Related Articles

Cost-Minimization Analysis of IgPro20, a Subcutaneous Immunoglobulin, in Japanese Patients With Primary Immunodeficiency.

Clin Ther. 2014 Sep 15;

Authors: Igarashi A, Kanegane H, Kobayashi M, Miyawaki T, Tsutani K

Abstract
PURPOSE: IgPro20, Hizentra(®) an L-proline-stabilized 20% human subcutaneous immunoglobulin (SCIG), has been shown in a Phase III pivotal study to be well tolerated and efficacious in adult and pediatric Japanese patients with primary immunodeficiency. Economic aspects of SCIG treatment in comparison with previous intravenous immunoglobulin (IVIG) therapy were analyzed in this Phase III study in Japan.
METHODS: Twenty-four Japanese patients with primary immunodeficiency on IVIG treatment were switched to IgPro20 at an equivalent dose (full analysis set). The study consisted of a screening period, an IVIG treatment period with 3 planned infusions every 3 or 4 weeks, a 12-week SCIG wash-in and wash-out period, and a 12-week SCIG efficacy period. The difference in medical cost and productivity loss resulting from changes in hospital frequency between the SCIG and IVIG treatment was evaluated. Information about treatment cost was collected as part of the Life Quality Index questionnaire. In addition, productivity loss and hospital-related absenteeism were evaluated.
FINDINGS: Life Quality Index scores for all domains were higher with SCIG than with IVIG in this patient population. In the full analysis set, the mean (SD) Life Quality Index score of the Costs domain increased from 45.1 (26.34) at Week 1 (IVIG period) to 71.9 (18.52) at Week 24 (end of the SCIG efficacy period), representing a mean change of 26.74 and a large score improvement effect size (1.01). Median productivity loss was reduced by 60% from baseline to Weeks 12 and 24. This resulted in a reduction in costs of JPY 10,875 per patient per month at Weeks 12 and 24. Subcutaneous treatment with IgPro20 also reduced hospital-related absenteeism. The number of patients, parents, or guardians who were not absent from work or housework duties and had no reduction in working time increased from 4 (17.4%) at Week 1 to 9 (39.1%) at Week 24. Similar results were obtained in the per-protocol set (n = 21).
IMPLICATIONS: Switching from IVIG to SCIG reduced markedly productivity loss and hospital-related absenteeism. The reduction in hospital visit frequency due to the use of home-based IgG therapy enabled by the change in administration route is expected to produce an important pharmacoeconomic benefit in Japan. Study Code: ZLB06_002CR, ClinicalTrials.gov identifier: NCT01199705.

PMID: 25236916 [PubMed – as supplied by publisher]

Powered by WPeMatico

Filed Under: Research

Progressive neurodegenerative syndrome in a patient with x-linked agammaglobulinemia receiving intravenous immunoglobulin therapy.

September 23, 2014 By Manish Butte

Related Articles

Progressive neurodegenerative syndrome in a patient with x-linked agammaglobulinemia receiving intravenous immunoglobulin therapy.

Cogn Behav Neurol. 2014 Sep;27(3):155-9

Authors: Sag AT, Saka E, Ozgur TT, Sanal O, Ayvaz DC, Elibol B, Kurne AT

Abstract
A progressive encephalopathy of unknown etiology has been described in patients with primary immunodeficiency disorders. In this report, we characterize the clinical features of this progressive neurodegenerative dementing disorder in a young man with Bruton agammaglobulinemia, through neuropsychological tests and a video sequence. The clinical course of the encephalopathy seems rather uniform: Cognition, especially frontal lobe function, is affected in the early stages, and some patients develop movement disorders. The syndrome causes severe cognitive and physical disability, and can eventually be fatal. The autoimmunity results from dysregulated immune responses, but the underlying mechanism has not yet been fully explained.

PMID: 25237746 [PubMed – in process]

Powered by WPeMatico

Filed Under: Research

Deficiency of Interleukin-1 Receptor-associated Kinase 4 Presenting as Fatal Pseudomonas aeruginosa Bacteremia in Two Siblings.

September 19, 2014 By Manish Butte

Related Articles

Deficiency of Interleukin-1 Receptor-associated Kinase 4 Presenting as Fatal Pseudomonas aeruginosa Bacteremia in Two Siblings.

Pediatr Infect Dis J. 2014 Sep 17;

Authors: Stergiopoulou T, Walsh TJ, Seghaye MC, Netea MG, Casanova JL, Moutschen M, Picard C

Abstract
Interleukin-1 receptor-associated kinase 4 (IRAK-4) deficiency is a primary immunodeficiency of innate immunity. This is the case of a previous healthy toddler and his sibling, who both died of fulminant sepsis due to Pseudomonas aeruginosa. Subsequent genetic analysis demonstrated IRAK-4 deficiency with compound heterozygous splice mutations. Fulminant fatal Pseudomonas aeruginosa sepsis may be the first manifestation of IRAK-4 deficiency.

PMID: 25232776 [PubMed – as supplied by publisher]

Powered by WPeMatico

Filed Under: Research

A case of long-undiagnosed Common Primary Immunodeficiency in adulthood.

September 17, 2014 By Manish Butte

A case of long-undiagnosed Common Primary Immunodeficiency in adulthood.

Eur Ann Allergy Clin Immunol. 2014 Sep;46(5):184-8

Authors: Tirotta D, Durante V

Abstract
Common Variable Immunodeficiency (CVID) is one of the most common causes of Primary Immunodeficiency Disorders (PIDs) and of Primary Hypogammaglobulinemia in adulthood. Clinical features include variable combinations of infectious diseases, autoimmune diseases, lymphoproliferative disorders and gastrointestinal diseases. In this case report, delayed detection of the disease had a negative prognostic impact, despite prompt antibiotic and replacement therapy. The unfavourable prognosis was due to multi-organ failure (namely lungs, heart and liver) and to a number of chronic and acute infectious diseases.

PMID: 25224950 [PubMed – in process]

Powered by WPeMatico

Filed Under: Research

  • « Go to Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 694
  • Page 695
  • Page 696
  • Page 697
  • Page 698
  • Interim pages omitted …
  • Page 711
  • Go to Next Page »

Copyright © 2026 · Genesis Framework by StudioPress · WordPress · Log in